Gland Pharma Limited — PPTs, 20-05-2025: Investor Presentation

1. Financial Highlights:

Gland Pharma reported consolidated revenue of ₹142.5 Cr in Q4 FY25, down 7% YoY but up 3% QoQ; full-year revenue stable at ₹561.7 Cr (-1% YoY). Gross profit held steady at ₹93.7 Cr (66% margin). EBITDA fell 3% YoY to ₹34.8 Cr (24% margin), while PAT declined 3% YoY to ₹18.7 Cr (13% margin), indicating margin pressure. Base business revenue was ₹103.3 Cr (-12% YoY) with strong EBITDA (38%) and PAT (28%) margins. R&D spend totaled ₹50.3 Cr in Q4 (4.9% of sales). Net worth increased to ₹915 Cr; ROCE at 9% and RONW 8% softened slightly. Operating cash flow remained robust at ₹915 Cr.

2. Strategic Initiatives & Growth Drivers:

Gland Pharma introduced four new injectables in FY25, totaling 31 launches, and filed 24 ANDAs with 32 approvals to grow its complex injectable portfolio targeting a $6.5B US market. Capex is focused on scaling GLP-1 pen and cartridge capacity from 40M to 140M units, tapping into the diabetes segment. Biologics CDMO collaboration with Dr. Reddy’s will start contributing from FY26. Cenexi is expanding ampoule capacity and launching vaccine and ophthalmic gel lines, supported by a €60 Mn capex over three years aimed at high-value formulations like vials and pre-filled syringes.

3. Business Developments:

The company secured seven ANDA approvals and filed five more in Q4. Its complex injectable pipeline advanced with 15 co-development products slated for commercialization from FY27. Cenexi recovered from operational issues and is on track for positive EBITDA by Q3 FY26. USFDA inspections at Hyderabad plants concluded successfully. A final dividend of ₹18/share was proposed for FY25.

4. Market Position & Competitive Advantage:

Gland Pharma stands as a leading injectable generics player with seven vertically integrated plants, including oncology and biologics, issuing 371 US ANDA filings (318 approved). Its global footprint covers 60+ countries, with a B2B revenue model at 98%. Strong R&D and compliance enable rapid launches in complex segments. Cenexi’s advanced European CDMO presence focuses on specialty injectables and vaccines, supporting diversified growth.

5. Investor Implications:

While core generics face near-term margin and revenue headwinds, Gland Pharma’s strong pipeline, biologics CDMO expansion, and Cenexi’s turnaround offer solid medium-term growth potential. Key drivers include novel injectable scale-up, GLP-1 capacity expansion, and new product launches. Investors should monitor commercialization timelines, Cenexi’s margin recovery, and synergy gains. A stable balance sheet and steady dividends underpin a constructive outlook with moderate execution risk.